Henry Fung, Co-Chair of Department of Cancer Medicine at Fox Chase Cancer Center, shared on X:
”Elranatamab is moving from salvage to center stage in multiple myeloma.
- MagnetisMM-3 established activity in advanced, triple-class-refractory disease.
- MagnetisMM-5 moved into earlier relapse – largely anti-CD38-naïve or daratumumab-sensitive.
- MagnetisMM-32 extended the strategy to anti-CD38- and lenalidomide-exposed disease, with a positive PFS topline.
Now come the two most consequential challenges:
- MagnetisMM-6: EDR versus D-VRd—challenging the frontline crown.
- MagnetisMM-7: elranatamab versus lenalidomide after ASCT – challenging maintenance.
But MM-7 raises an important question: is lenalidomide alone still the right comparator? The more contemporary challenger should arguably be Dara-R – and perhaps Isa-R.
Elranatamab is becoming a major player in myeloma. The remaining questions are not only whether it wins, but where it belongs, how long to give it, and whether improved PFS ultimately translates into better OS and treatment sequencing.”
You can also read:
Multiple Myeloma in 2026: Comprehensive Clinical Update
